Lv1
28 积分 2022-03-16 加入
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
5小时前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1个月前
已完结
Endocytosis and intracellular trafficking of ErbBs
1个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
1个月前
已完结
Hijacking ERAD for targeted degradation of transmembrane proteins
2个月前
已完结
Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study
4个月前
已完结
Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
5个月前
已完结
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases
5个月前
已完结
皖公网安备34019202002308
